Cyltezo Shortage Update: What Patients Need to Know in 2026

Cyltezo in 2026: What's the Latest?

If you've been trying to fill a Cyltezo (Adalimumab-adbm) prescription and hitting dead ends, you're probably wondering: is there a Cyltezo shortage? The answer is nuanced. While there isn't an official FDA-reported shortage of Cyltezo as of early 2026, many patients are still struggling to find it at their local pharmacy. Here's what's really going on — and what you can do about it.

Is Cyltezo Still in Shortage?

Technically, no. The FDA's drug shortage database does not currently list Cyltezo as being in shortage. Boehringer Ingelheim, the manufacturer, continues to produce and distribute the medication. However, "not in shortage" at the national level doesn't mean your neighborhood pharmacy has it on the shelf.

The real issue isn't a manufacturing shortage — it's an access problem. Here's why:

• Over 10 adalimumab biosimilars are now competing for market share in the U.S.
• Pharmacies typically stock only one or two versions based on their most common insurance contracts.
• Some major PBMs shifted their preferred adalimumab product away from Cyltezo in 2025, reducing demand at many pharmacies.

The result? Even though Cyltezo is being manufactured, it may not be sitting on the shelf at the pharmacy you usually visit.

Why Is Cyltezo Hard to Find?

Several factors are making it difficult for patients to locate Cyltezo:

Formulary Shifts

Insurance companies and PBMs regularly renegotiate which drugs they prefer. In 2025, Optum Rx dropped Cyltezo from its preferred formulary in favor of Amjevita. When a PBM removes a drug from its preferred list, pharmacies respond by reducing their stock of that drug. For a deeper dive, read why Cyltezo is so hard to find.

Market Fragmentation

The adalimumab biosimilar market is crowded. With brands like Amjevita, Hyrimoz, Hadlima, Hulio, Yuflyma, Abrilada, and others all vying for prescriptions, pharmacy shelves have gotten competitive. Most pharmacies can't justify stocking all of them.

Specialty Distribution

Cyltezo is a biologic medication that often flows through specialty pharmacy channels rather than retail. If you're only checking chain pharmacies, you may be looking in the wrong place.

How Much Does Cyltezo Cost in 2026?

The cash price for Cyltezo remains steep — approximately $7,500 to $7,900 per month for a two-pen or two-syringe kit (a one-month supply). However, very few patients pay that full amount:

• With insurance: Most patients with commercial insurance pay $0 to $50 per month after copay assistance. Prior authorization is usually required.
• With a discount card: Prescription discount programs like SingleCare can bring the cost down to around $1,200–$1,300 per month.
• With manufacturer savings: Boehringer Ingelheim's Cyltezo Savings Copay Program may reduce your copay to as little as $0 for eligible commercially insured patients.

For more details on saving money, see our complete guide: How to Save Money on Cyltezo in 2026.

New Options in 2026

The adalimumab biosimilar market continues to evolve. Several developments are worth noting:

• More interchangeable products: Amjevita and Hyrimoz have both achieved interchangeable status, joining Cyltezo. This means more options that pharmacists can automatically substitute for Humira.
• High-concentration formulations: Cyltezo's high-concentration version (40 mg/0.4 mL) was approved in 2024. This means a smaller injection volume, which some patients prefer.
• Unbranded adalimumab-adbm: An unbranded version of Cyltezo (same drug, no brand name) is also available and may be priced lower.

If Cyltezo isn't available, these alternatives may be easier to find.

How to Find Cyltezo in Stock

Here's what you can do right now:

1. Check Medfinder. Use Medfinder to check real-time pharmacy availability near you.
2. Call specialty pharmacies. These pharmacies focus on biologics and are more likely to carry Cyltezo.
3. Contact your insurance. Ask which specialty pharmacies are in your network and whether home delivery is an option.
4. Reach out to Boehringer Ingelheim. Their patient support program can help connect you with pharmacies that stock Cyltezo.
5. Ask your doctor. They can help with prior authorization, switch you to an available alternative, or provide bridge samples.

For more tips, read our full guide: How to Find Cyltezo in Stock Near You.

Final Thoughts

The Cyltezo "shortage" in 2026 isn't really a manufacturing shortage — it's a market access challenge. The medication exists, but navigating the web of insurance formularies, pharmacy stocking decisions, and specialty distribution can feel impossible.

The key is to be proactive: check availability using tools like Medfinder, explore your insurance options, and stay in close contact with your doctor. If Cyltezo isn't accessible, there are several effective alternatives available. Whatever you do, don't skip doses — your health is too important.